In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

Mayo Clin Proc. 2021 Mar;96(3):817-818. doi: 10.1016/j.mayocp.2020.12.029. Epub 2021 Jan 11.

Authors

Zelalem Temesgen¹, Saad S Kenderian², Andrew D Badley³

Affiliations

¹ Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
² Division of Hematology, T Cell Engineering, Mayo Clinic, Rochester, MN.
³ Division of Infectious Diseases, Department of Molecular Medicine, Mayo Clinic, Rochester, MN.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Cohort Studies
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
Granulocyte-Macrophage Colony-Stimulating Factor
lenzilumab